Regeneron to Establish Global Capability Centre in Hyderabad, Expand Life Sciences Operations in India
US Biotechnology Major Plans Hundreds of New Jobs Across AI, Clinical Research and Digital Operations
Bari Kowal, Senior Vice President, Development Operations, Portfolio Management and Biostatistics Data Management at Regeneron, Rajiv Onat, Executive Director of Regeneron GCC, with Telangana Minister for Information Technology, Electronics, Communications, Industries & Commerce and Legislative Affairs Duddilla Sridhar Babu in Hyderabad on Tuesday.
Hyderabad: US-based biotechnology company Regeneron Pharmaceuticals Inc. has announced plans to establish a Global Capability Centre (GCC) in Hyderabad, marking a major strategic expansion of its global operations and strengthening Telangana’s growing position as a global life sciences and technology hub.
The Regeneron GCC is expected to become operational in the second half of 2026 and will create hundreds of new roles in the coming years across areas including drug development, digital technologies, artificial intelligence, clinical trial operations, analytics and commercial functions.
The company said the Hyderabad facility will complement its global operations across North America, Europe and Asia while building on its existing presence in Bengaluru established in 2022.
Headquartered in the United States, Regeneron is a global biotechnology company with 15 approved or authorised medicines and nearly 50 pipeline candidates across multiple therapeutic areas. Its medicines currently reach patients in more than 100 countries.
Announcing the investment, Telangana Minister for Information Technology, Electronics, Communications, Industries & Commerce and Legislative Affairs Duddilla Sridhar Babu said Hyderabad’s expanding life sciences ecosystem and talent base continue to attract global investments.
“Hyderabad has a growing stature as a global hub for life sciences, biotechnology and advanced digital innovation. Telangana’s strengths across biotechnology, clinical research, AI, data sciences and healthcare innovation make it an ideal destination for global companies building high-value innovation and operational centres,” he said.
The minister noted that Genome Valley, the state’s upcoming Green Pharma City initiative and Hyderabad’s established pharmaceutical ecosystem have contributed to the city’s emergence as a preferred destination for biotechnology and research-driven investments.
According to the company, the new GCC will house teams focused on data management, statistical programming, AI, digital technology, clinical trial operations, insights and analytics.
Bari Kowal, Senior Vice President, Development Operations, Portfolio Management and Biostatistics Data Management at Regeneron, said the new centre represents a long-term investment in the company’s future global growth.
“Hyderabad has established itself as a world-class hub for life sciences and technology talent, and we are proud to expand our presence there,” Kowal said.
Rajiv Onat, Executive Director of Regeneron GCC, said the centre would focus on building exceptional talent and enabling teams to contribute to science-led innovation and patient-focused healthcare solutions.
Hyderabad currently hosts more than 450 Global Capability Centres and has emerged as one of India’s fastest-growing destinations for multinational technology, healthcare and life sciences operations.
Industry observers believe the Regeneron investment further strengthens Telangana’s positioning as a global hub for biotechnology innovation, AI-driven healthcare research and advanced pharmaceutical operations.
